Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
The Eli Lilly emblem seems on the corporate’s workplace in San Diego, California, US, Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech firm Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly pays $3.25 billion upfront, and the remaining funds are contingent upon medical, regulatory…
